Back to Search
Start Over
The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
- Source :
-
Fundamental & Clinical Pharmacology . Jun2009, Vol. 23 Issue 3, p339-344. 6p. 3 Graphs. - Publication Year :
- 2009
-
Abstract
- To investigate the effect of chronic oral arginine aspartate on the growth hormone (GH), GH-releasing hormone (GHRH), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) secretions in healthy volunteers. Twenty-three healthy non-athlete volunteer males were administered arginine aspartate (30 g) orally once daily at 21:00 h for 21 consecutive days. Subjects were hospitalized on days 0, 1, 3, 5, 7, 14 and 21 of treatment. At each hospitalization, concentrations of GHRH, GH, IGF-1 and IGFBP-3 were measured over 4 h after arginine aspartate intake. GH, IGF-1 and IGFBP-3 concentrations were also determined over 12 h at days 0, 1 and 21. Compared with day 1, 4 h GH levels dropped at day 5 and subsequently rose to levels not significantly different from initial ones. The latter was substantiated by 12 h GH levels that did not significantly change from days 1 to 21. GHRH levels were not statistically different, although there was a trend in median values that seemed to inversely mirror those of GH. This dynamic over the course of the study for GH and GHRH was accompanied by a general decrease in IGF-1 and IGFBP-3. In healthy volunteers, a chronic oral treatment with 30 g/day arginine aspartate is followed by a decrease in IGF-1 and IGFBP-3 secretions. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07673981
- Volume :
- 23
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Fundamental & Clinical Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 40642476
- Full Text :
- https://doi.org/10.1111/j.1472-8206.2009.00716.x